Cargando…
Lack of access to CDK4/6 inhibitors for premenopausal patients with metastatic breast cancer in Brazil: estimation of the number of premature deaths
PURPOSE: A CDK4/6 inhibitor (CDK4/6i) combined with endocrine therapy is the standard of care for patients with hormone receptor-positive (HR+) and HER2-negative (HER2-) metastatic breast cancer (MBC). However, the incorporation of these agents into clinical practice remains challenging. This study...
Autores principales: | Reinert, Tomás, Pellegrini, Rodrigo, Barrios, Carlos Henrique |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cancer Intelligence
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7434502/ https://www.ncbi.nlm.nih.gov/pubmed/32863875 http://dx.doi.org/10.3332/ecancer.2020.1081 |
Ejemplares similares
-
Estimation of the Number of Brazilian Women Living With Metastatic Breast Cancer
por: Reinert, Tomás, et al.
Publicado: (2020) -
Estimation of Premature Deaths From Lack of Access to Anti-HER2 Therapy for Advanced Breast Cancer in the Brazilian Public Health System
por: Debiasi, Márcio, et al.
Publicado: (2016) -
Cost-effectiveness of breast, lung, colon, prostate and cervical cancer outcomes in Brazil: a worldwide comparison
por: Pellegrini, Rodrigo, et al.
Publicado: (2021) -
Access to high-cost drugs for advanced breast cancer in Latin America, particularly trastuzumab
por: Barrios, Carlos Henrique, et al.
Publicado: (2019) -
The Effects of Different Hormones on Supraventricular and Ventricular Premature Contractions in Healthy Premenopausal Women
por: Tsougos, Elias, et al.
Publicado: (2021)